Its safety comes from its biochemistry, not from marketing claims about naturalness
Athletes who want quick results might prefer direct NAD+ supplementation through IV
A composite analysis of 8 cardiovascular outcomes trials completed in 2021 demonstrated reduced incidence of major cardiovascular events by 14% and cardiovascular death by 13% (NCT01147250, NCT01179048, NCT01720446, NCT01144338, NCT02465515, NCT01394952, NCT02692716, NCT03496298)
However, recent policy changes are reshaping access, especially in California
At the high end for strong responders (30%), thats approximately 51 lbs
Phase 2 clinical research published in 2023 documented metabolic effects that exceeded those reported for any prior incretin agonist